Pulmonary Embolism Clinical Trial
Official title:
Assessing the Risk of Pulmonary Embolism in Patients After Hospitalization for First Episode of Syncope
Acute pulmonary embolism (APE) is a common disease, which involves significant morbidity and
mortality. The clinical presentation of APE has many faces but it is acceptable to suspect
this disease when the patient presenting with at least one of the following: shortness of
breath, pleuritic chest pain, cough, sub-febrile fever or hemoptysis.
The relationship between syncope and APE is not entirely clear. Prandoni et al conducted a
systematic process for the exclusion / confirmation of APE all patients hospitalized for a
first investigation of syncope. In this study APE was diagnosed in about 17% of the
patients. In 12.7% of patients with an alternative explanation for syncope APE was
diagnosed. Interestingly, 25% of the patients had no other manifestation of pulmonary
embolism apart from the syncope itself.
According to the updated clinical guidelines, APE should not be routinely tested as an
etiology for syncope and not systematically excluded. According to the new data presented by
Prandoni et al, this means that a significant percentage of patients hospitalized for an
investigation of syncope are discharged when they are suffering from APE (in most cases
probably an event of unprovoked pulmonary embolism) without treatment with anticoagulants,
making them particularly prone to PE recurrence.
Aim. To examine the incidence of pulmonary embolism (Pulmonary Embolism, PE), and VTE
(venous thromboembolism, VTE) in patients hospitalized for a first investigation of syncope.
Method.
Study population:
The study is a retrospective, multicenter cohort study, conducted at Rambam Health Care
Campus and Sourasky Medical Center, Tel Aviv and includes all Clalit HMO insured patients
who were admitted for investigation of first event of syncope from 2006 to 2013 (diagnosis
on admission- syncope and collapse (ICD9 code 427.31)).
Inclusion criteria:
- Patients over 18 years old during study period.
- On admission diagnosis of syncope and collapse (ICD9 code 427.31).
- Patients are insured by Clalit Health Services.
Exclusion criteria:
- Hospitalization during the study period for additional event of syncope.
- Patients receiving anticoagulation on recruitment.
- Patients investigated for APE during hospitalization (by testing for D-dimer,
computerized tomography angiography or perfusion-ventilation lung scan).
- Patients who began treatment anticoagulation, not because of VTE, during study period.
Study design The research is divided into two main stages. At the first phase data of the
relevant study population will be collected from the computerized medical record of the two
medical centers mentioned above and according to the inclusion and exclusions criteria
listed above.
In the second phase we will examine in the study population the occurrence of PE or DVT
within 36 months from hospitalization.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05050617 -
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
|
||
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Completed |
NCT03915925 -
Short-term Clinical Deterioration After Acute Pulmonary Embolism
|
||
Completed |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT04454554 -
Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
|
||
Completed |
NCT03173066 -
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
|
Phase 1 | |
Terminated |
NCT03002467 -
Impact Analysis of Prognostic Stratification for Pulmonary Embolism
|
N/A | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02611115 -
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
|
N/A | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT01326507 -
Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism
|
N/A | |
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT02476526 -
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00780767 -
Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism
|
Phase 2 | |
Completed |
NCT00816920 -
Natural History of Isolated Deep Vein Thrombosis of the Calf
|